HK Stock Market Move | SKB BIO(06990) rose over 6% as ASCO released major lung cancer data. sac-TMT is about to enter commercialization phase overseas.

SKB BIO (06990) rose more than 6%, as of the time of writing, it increased by 5.33%, reaching 419.4 Hong Kong dollars, with a turnover of 29.2642 million Hong Kong dollars. On the news side, recently, SKB BIO verbally reported the results of the Phase III OptiTROP-Lung05 study of sac-TMT in combination with K drug for first-line treatment of PD-L1TPS1% NSCLC at the 2026 ASCO conference. Industrial believes that the company's core product, sac-TMT, is progressing smoothly in global clinical trials and continues to validate its best global potential among similar products worldwide. Overseas, it is about to enter the commercialization stage, opening up imagination space with Merck. Industrial continued to point out that Merck previously announced that the global key Phase III TroFuse-005 study of sac-TMT monotherapy in the treatment of 3L+ endometrial cancer patients achieved the primary endpoints of OS and PFS, making it the first and only ADC to achieve this goal for endometrial cancer patients in this treatment setting. Merck has initiated 17 registered clinical trials around sac-TMT and is expected to continuously read out more global Phase III data in the future, continuously validating the global market potential of the product.